European Commission Research & Innovation Initiatives and Programme Opportunities
Return to overview

European Partnership for Fostering a European Research Area for Health (ERA4Health)

Snapshot overview

The European Partnership for Fostering a European Research Area for Health (ERA4Health) is a partnership bringing together 27 funding organisations and 33 partners from 22 countries, covering 17 of the 27 European Union (EU) Member States, 3 third countries associated to Horizon Europe (Israel, Norway, Turkey), and 2 third countries (Egypt and Taiwan). It aims to support transnational medical research across prevention, diagnosis, and treatment, capacity building, and responsible research and innovation (RRI).
Under the 2024 Work Programme, two calls for proposals are open: NutriBrain focused on modulation of brain ageing through nutrition and healthy lifestyle and NANOTECMEC focused on nano and advanced technologies for disease prevention, diagnostic and therapy.

Name

European Partnership for Fostering a European Research Area for Health (ERA4Health)

Institution/ DG/ Agency responsible at EU-level

Directorate-General for Research and Innovation (DG RTD) and the Institute of Health Carlos III (Spain)

Work programme

2024 EU4Health Work Programme

Programme

ERA4Health is a partnership under Horizon Europe covering 2022-2028.

Programme budget

The total indicative budget for the duration of ERA4Health is EUR 110 million.

Project budget

Depending on the specific project. For further detail, please see below:

  • NutriBrain: EUR 19,934,000
  • NANOTECMEC: EUR 18,540,000
Type of funding

Grant

Target participants

Project partners from countries participating in the call for proposals

Programme scope

ERA4Health is being implemented in two phases. Phase 1 focuses on nutrition and lifestyle-related diseases, cardiovascular disease and nanomedicines. Phase 2 of ERA4Health will focus on investigator-initiated clinical studies.

Participant criteria

Joint research proposals for NutriBrain and NANOTECMEC may be submitted by applicants belonging to one of the following categories:

  • Academia
  • Clinical/public health sector
  • Enterprises
  • Operational stakeholders

Each application must include partners from at least two categories among academia, public sector, and enterprises.

Project duration
  • NutriBrain: Initial project duration of 36 months
  • NANOTECMEC: Initial project duration of 36 months
Average time from submission to project kick-off
  • NutriBrain:
    • Deadline for full proposal submission 27 May 2024
    • Expected project start December 2024-May 2025
  • NANOTECMEC:
    • Deadline for full proposal submission 13 June 2024
    • Expected project start December 2024-May 2025
R&D stage
  • NutriBrain: Pilot test interventions or upscaling of existing pilot test interventions are eligible
  • NANOTECMEC: Pre-clinical and clinical studies are eligible
Intellectual property

Unknown

Project database
  • NutriBrain: Overview here, Call for proposals here
  • NANOTECMEC: Overview here, Call for proposals here
Status
  • NutriBrain: Open
    • Call Pre-announcement: 12 October 2023
    • Publication of the call: 03 November 2023
    • Deadline for the pre-proposals submission: 15 January 2024
    • Deadline for the full-proposals submission: 27 May 2024
  • NANOTECMEC: Open
    • Call Pre-announcement: 18 October 2023
    • Publication of the call: 14 November 2023
    • Deadline for the pre-proposals submission: 30 January 2024
    • Deadline for the full-proposals submission: 13 June 2024

Contact details & more information

ERA4Health – Overview
Strategic Research and Innovation Agenda

 

Return to overview

This tool was created by FTI Consulting for GSK and EFPIA.
For all enquiries please contact niro@fticonsulting.com
Privacy policy

This tool was created by FTI Consulting
for GSK and EFPIA.
For all enquiries please contact niro@fticonsulting.com
Privacy policy

What type of funding are you looking for?

  • Grant:
    Grants are direct financial contributions from the European Union budget awarded by way of a donation to third-party beneficiaries (usually non-profit-making organisations) engaged in activities that serve EU policies.
  • Loan:
    Loans are measures of financial support provided on a complementary basis from the budget in order to address specific policy objectives of the European Union. Such instruments are implemented in partnership with public and private institutions such as banks, venture capitalists or angel investors.

What stage of development are you seeking R&I funding for?

  • Basic science: Basic science covers the various exploratory steps even prior to discovery
  • Discovery: Drug discovery aims to find potential disease-altering targets, such as a gene or a protein in humans. Prior to testing candidate compounds for safety
  • Preclinical development: Preclinical development concerns the testing of candidate compounds for safety in specific indications or disease conditions. Introduction of candidate compound in living biological systems (animals)
  • Phase 1 clinical trials: These are the first clinical trials on humans(usually 20-80 volunteers) testing the safety, side effects, best dose, and timing of a new treatment
  • Phase 21/2b clinical trials: This is the follow-up trial with roughly 100 to 500 patients to analyse efficacy and safety
  • Phase 3 clinical trials: These trials usually involve several hundreds to many thousands patients and tests the results of earlier clinical trials on larger populations to generate robust data on safety, efficacy and benefit-risk relationships of the medicine. Comparison to placebo and/or active comparator (best standard treatment)
  • Registration & launch: This concerns post-study, prior to launch, activities related to market launch. That can include, among others, marketing authorisation, regulatory activities, post-study communication or HTA
  • Introduction & delivery: This concerns all post-launch activities

What do you want to develop?

  • Treatment or vaccine:
    Refers to a drug or vaccine
  • Diagnostic or medical device:
    Refers to diagnostics and medical devices
  • Platform:
    Refers to a digital health platform or medical app
  • Knowledge:
    Refers to conducting research to help build our understanding on a topic
  • Standards:
    Refers to creating a benchmark for a specific issue

What type of organisation are you?

  • Small & medium-sized enterprises:
    <250 employees, annual revenue <EUR 50,000,000) or balance sheet < EUR43 million. This applies to individual firms only. If part of larger group, check the User Guide: https://ec.europa.eu/docsroom/documents/42921
  • Large enterprises:
    >250 employees or annual revenue > EUR 50,000,000. Non-profit organisation (non-governmental organisations that are recognised with a non-profit status)
  • Non-profit organisations:
    Non-governmental organisations that are recognised with a non-profit status
  • Academic:
    Linked to a university or equivalent
  • Public:
    Local, regional, federal government representative

What stage of diagnostics development does your research aim to cover?

  • Development:
    Product development
  • Validation:
    Lab and clinical validation
  • Evaluation & Authorisation:
    Regulatory approvals
  • Access:
    Monitoring

What stage of medicine or vaccine development does your research aim to cover?

  • Discovery and development:
    Identification of promising compounds for development and initial experiments to gather information
  • Preclinical research:
    Laboratory and animal testing to answer basic questions about safety
  • Phase 0 (clinical):
    Testing on limited number of subjects at subtherapeutic doses
  • Phase I (clinical):
    Testing on <100 healthy subjects with the disease/condition
  • Phase II (clinical):
    Testing on up to several hundred subjects with the disease/condition
  • Phase III (clinical):
    Testing on 300 to 3,000 volunteers with the disease/condition
  • Preregistration / Phase IV (clinical):
    Testing on several thousand volunteers with the disease/condition
  • Clinical (unspecified):
    Clinical phase unknown
  • Evaluation & Authorisation:
    Activities relating to marketing authorisation
  • Access:
    Monitoring

Where are you based?

  • Africa : Algeria, Angola, Benin, Botswana, Burkina Faso, Burundi, Cabo Verde, Cameroon, Central African Republic (CAR), Chad, Comoros, Congo (Democratic Republic of the), Congo (Republic of the), Cote d’Ivoire, Djibouti, Egypt, Equatorial Guinea, Eritrea, Eswatini, Ethiopia, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Kenya, Lesotho, Liberia, Libya, Madagascar, Malawi, Mali, Mauritania, Mauritius, Morocco, Mozambique, Namibia, Niger, Nigeria, Rwanda, Sao Tome and Principe, Senegal, Seychelles, Sierra Leone, Somalia, South Africa, South Sudan, Sudan, Tanzania, Togo, Tunisia, Uganda, Zambia, Zimbabwe
  • America (non-US & Canada) : Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba, Dominica, Dominican Republic, Ecuador, El Salvador, Grenada, Guatemala, Guyana, Haiti, Honduras, Jamaica, Mexico, Nicaragua, Panama, Paraguay, Peru, Saint Kitts and Nevis, Saint Lucia, Saint Vincent and the Grenadines, Suriname, Trinidad and Tobago, Uruguay, Venezuela
  • Asia-Pacific : Afghanistan, Australia, Bangladesh, Bhutan, Burma, Brunei, Cambodia, China (including special administrative regions of Hong Kong and Macau), Cook Islands, Federated States of Micronesia, Fiji, India, Indonesia, Japan, Kiribati, Laos, Malaysia, Maldives, Marshall Islands, Mongolia, Nepal, New Caledonia, New Zealand, Niue, North Korea, Pakistan, Palau, Papua New Guinea, Philippines, Singapore, Solomon Islands, South Korea, Sri Lanka, Taiwan, Thailand, Timor-Leste, Tonga, Tuvalu, Vanuatu, Vietnam
  • Europe (non-EU) : Albania, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Georgia, Iceland, Kosovo, Liechtenstein, Moldova, Monaco, Montenegro, North Macedonia, Norway, Russia, San Marino, Serbia, Switzerland, Turkey, Ukraine, United Kingdom
  • European Union (EU) : Austria, Belgium, Bulgaria, Croatia, Republic of Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
  • Middle East : Cyprus, Lebanon, Syria, Iraq, Iran, Israel, Jordan, Saudi Arabia, Kuwait, Qatar, Bahrain, United Arab Emirates, Oman, Yemen
  • United States (US) & Canada : United States, Canada

What type of organisation are you?

  • Small and medium-sized enterprise (SME):
    Staff headcount 50 < and turnover ≤ EUR 10 m or balance sheet total ≤ EUR 10 m (small); Staff headcount 250 < and turnover ≤ EUR 50 m or balance sheet total ≤ EUR 43 m (medium)
  • Large enterprise:
    Staff headcount > 250
  • Non-profit organisation:
    Association, foundation, or equivalent
  • Academic:
    University, research institute, or equivalent
  • Individual:
    Private citizen
  • Public sector:
    Local, regional, federal government representative
  • Other:
    None of the above or uncertain